Abstract 55P
Background
Routine methods for MSI/dMMR for CRC pts detection are PCR/IHC, however the data on the benefit of ICI in cases with discordant results is limited. The clinical validity of NGS as a promising approach for MSI detection is currently unclear.
Methods
Patients with MSI+ (PCR) or dMMR (IHC) colorectal cancer (CRC) were eligible (NCT06414304). All patients received immune checkpoint inhibitors (ICI) and had pre-treatment FFPE and liquid biopsy (LB) samples available for central MSI/dMMR testing with PCR/IHC (FFPE) and with NGS (Atlas Pro panel) (FFPE and LB).
Results
A total of 32 patients were included, 22 patients with stages II-III received ICI preoperatively, 10 – for advanced disease; 28 were available for response assessment. ORR in ITT population was 46%. Among 4 patients with discordant results (PCR vs IHC), ORR was 0% (p>0.05). In patients with MSI+ FFPE or MSI+ LB by NGS (n=23), ORR was 57% (p>0.05). Among pts with available LB (n=26), ORR was higher when LB samples were MSI+ (56%) vs MSS (25%) with p>0.05. Among MSI+ by NGS (LB) cases two were pMMR by IHC. Both cases had SD and were MSI+ by PCR and NGS (FFPE). None of the patients had MSI+ by NGS (LB) and MSS by PCR. Patients with DC had a median blood MSI burden of 0.07 (range, 0-0.77), whereas median MSI burden of pts with PD was 3.76 (range, 2.44-5.08) (p=0.03). Table: 55P
ORR by MSI analysis via different methods
| NGS (FFPE) | NGS (FFPE) | NGS (LB) | NGS (LB) | ||
| MSI | MSS | MSI | MSS | ||
| IHC (FFPE) | dMMR | 50% (n=16) | 0% (n=1) | 75% (n=12) | 33% (n=3) |
| IHC (FFPE) | pMMR | 0% (n=3) | n=0 | 0% (n=2) | 0% (n=1) |
| PCR (FFPE) | MSI | 45% (n=20) | 100% (n=1) | 44% (n=16) | 33% (n=3) |
| PCR (FFPE) | MSS | n=0 | 0% (n=1) | n=0 | 0% (n=1) |
Conclusions
Patients with MSI+ by PCR may experience different ICI benefits based on IHC status. Patients with MSI+ LB have better ORR. MSI burden analysis in pre-treatment LB samples is associated with better treatment outcomes. Further research is warranted.
Editorial acknowledgement
Clinical trial identification
NCT06414304.
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (Grant №22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Early cancer detection from liquid biopsy using cell-free RNA
Presenter: Joao Curado
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Numb serves as a prognostic biomarker and promotes lung adenocarcinoma brain metastasis
Presenter: Yanyan Zhao
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Integrin-fibronectin interplay is a pivotal biological and clinical determinant in papillary thyroid carcinoma
Presenter: Domenico Rocco
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Correlation of IL-6 and c-reactive protein levels with the stage, differentiation and types of colorectal cancer
Presenter: MOHAMED MAHBOOB ALI
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - RAS mutation status and mutation type as potential predictive biomarkers for thrombosis in metastatic colorectal cancer: A tertiary center 12-year cohort analysis
Presenter: José Leão Mendes
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Assessment of cancer testis antigen 45 for diagnostic and prognostic applications in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Integrative omics workflow identifies credible druggable targets in high-grade serous cancer
Presenter: Taru Muranen
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Response of gastric adenocarcinoma to neoadjuvant chemotherapy with respect to the presence or absence of HER2 overexpression: A prospective observational study
Presenter: Pratap Deb
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - NSCLC genomic complexity: Insights from comprehensive molecular profiling in the era of precision medicine
Presenter: Preeti Paliwal
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Identifying blood-based proteomic mediators of cancer-associated cachexia in non-small cell lung cancer in the TRACERx study
Presenter: Rachel Scott
Session: Cocktail & Poster Display session
Resources:
Abstract